يعرض 1 - 20 نتائج من 20 نتيجة بحث عن '"ovary polycystic disease/dm [Disease Management]"', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37218
    Medical Journal of Australia
    Click here for full text options
    LibKey Link

  2. 2
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37218
    Medical Journal of Australia
    LibKey Link

  3. 3
  4. 4
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36941
    Clinical Endocrinology
    Click here for full text options
    LibKey Link

  5. 5
  6. 6
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36941
    Clinical Endocrinology
    Click here for full text options
    LibKey Link

  7. 7
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39707
    Click here for full text options
    LibKey Link

  8. 8
    Electronic Resource
  9. 9
    Electronic Resource
  10. 10
  11. 11
    Electronic Resource
  12. 12
  13. 13
  14. 14
    Electronic Resource

    المؤلفون: Teede H.J., Norman R.J., Joham A.E.

    مصطلحات الفهرس: estrogen/ec [Endogenous Compound], acne, amenorrhea/dt [Drug Therapy], anovulation, anxiety, body image, body mass, cardiovascular risk, cyanocobalamin deficiency/si [Side Effect], depression, diabetes mellitus/di [Diagnosis], diarrhea/si [Side Effect], drug indication, drug safety, evidence based practice, female, female infertility/dt [Drug Therapy], high risk population, hirsutism/dt [Drug Therapy], hirsutism/th [Therapy], hormone determination, human, hyperandrogenism/dt [Drug Therapy], insulin resistance, lactic acidosis/si [Side Effect], lifestyle modification, low drug dose, menstruation disorder, metabolic syndrome X, nausea/si [Side Effect], non insulin dependent diabetes mellitus/dt [Drug Therapy], oligomenorrhea/dt [Drug Therapy], oral glucose tolerance test, ovary follicle, ovary polycystic disease/di [Diagnosis], ovary polycystic disease/dm [Disease Management], ovary polycystic disease/dt [Drug Therapy], ovary polycystic disease/et [Etiology], pathophysiology, patient counseling, estrogen/po [Oral Drug Administration], gestagen/dt [Drug Therapy], gonadotropin/dt [Drug Therapy], insulin/ec [Endogenous Compound], medroxyprogesterone acetate/dt [Drug Therapy], metformin/ae [Adverse Drug Reaction], metformin/dt [Drug Therapy], Muellerian inhibiting factor/ec [Endogenous Compound], oral contraceptive agent/dt [Drug Therapy], oral contraceptive agent/po [Oral Drug Administration], spironolactone/dt [Drug Therapy], clinical practice, practice guideline, risk reduction, self esteem, short survey, symptom, ultrasound, women's health, androgen/ec [Endogenous Compound], antiandrogen/dt [Drug Therapy], clomifene/dt [Drug Therapy], cyproterone acetate/dt [Drug Therapy], eflornithine/dt [Drug Therapy], eflornithine/tp [Topical Drug Administration], estrogen/do [Drug Dose], estrogen/dt [Drug Therapy], Short Survey

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29749
    Click here for full text options
    LibKey Link

  15. 15
    Electronic Resource
  16. 16
  17. 17
  18. 18
    Electronic Resource

    المؤلفون: Teede H.J., Norman R.J., Joham A.E.

    مصطلحات الفهرس: estrogen/ec [Endogenous Compound], acne, amenorrhea/dt [Drug Therapy], anovulation, anxiety, body image, body mass, cardiovascular risk, cyanocobalamin deficiency/si [Side Effect], depression, diabetes mellitus/di [Diagnosis], diarrhea/si [Side Effect], drug indication, drug safety, evidence based practice, female, female infertility/dt [Drug Therapy], high risk population, hirsutism/dt [Drug Therapy], hirsutism/th [Therapy], hormone determination, human, hyperandrogenism/dt [Drug Therapy], insulin resistance, lactic acidosis/si [Side Effect], lifestyle modification, low drug dose, menstruation disorder, metabolic syndrome X, nausea/si [Side Effect], non insulin dependent diabetes mellitus/dt [Drug Therapy], oligomenorrhea/dt [Drug Therapy], oral glucose tolerance test, ovary follicle, ovary polycystic disease/di [Diagnosis], ovary polycystic disease/dm [Disease Management], ovary polycystic disease/dt [Drug Therapy], ovary polycystic disease/et [Etiology], pathophysiology, patient counseling, estrogen/po [Oral Drug Administration], gestagen/dt [Drug Therapy], gonadotropin/dt [Drug Therapy], insulin/ec [Endogenous Compound], medroxyprogesterone acetate/dt [Drug Therapy], metformin/ae [Adverse Drug Reaction], metformin/dt [Drug Therapy], Muellerian inhibiting factor/ec [Endogenous Compound], oral contraceptive agent/dt [Drug Therapy], oral contraceptive agent/po [Oral Drug Administration], spironolactone/dt [Drug Therapy], clinical practice, practice guideline, risk reduction, self esteem, short survey, symptom, ultrasound, women's health, androgen/ec [Endogenous Compound], antiandrogen/dt [Drug Therapy], clomifene/dt [Drug Therapy], cyproterone acetate/dt [Drug Therapy], eflornithine/dt [Drug Therapy], eflornithine/tp [Topical Drug Administration], estrogen/do [Drug Dose], estrogen/dt [Drug Therapy], Short Survey

  19. 19
    Electronic Resource
  20. 20